Clinical Trials Logo

Amplification clinical trials

View clinical trials related to Amplification.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05653999 Recruiting - Hearing Loss Clinical Trials

Assessing Speech Perception and Amplification Benefit During Infancy

Start date: March 10, 2023
Phase:
Study type: Observational

The goal of this project is to compare aided and unaided speech discrimination among infants with hearing loss and a cohort of infants with typical hearing. Working Hypothesis: Among this group of infants with hearing loss, performance will be significantly better when infants are tested while using amplification (i.e., aided condition) compared to when tested without amplification (i.e., unaided condition). Infants fit with optimally programmed amplification will perform similarly to the infants with typical hearing on speech discrimination tasks.

NCT ID: NCT01168050 Recruiting - Stage IV Melanoma Clinical Trials

Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.

NILOMEL
Start date: July 2010
Phase: Phase 2
Study type: Interventional

NILOMEL is a phase II multicentric uncontrolled open national trial assessing the efficacy of Nilotinib in first or second line treatment of primary melanomas , stage III unresectable melanomas, or Stage IV melanomas with c-KIT mutation or amplification. The primary objective is overall response rate (partial and complete response) according to RECIST 1.1 criteria, assessed using CT-SCAN (stage IV melanoma) or MRI (unresectable melanoma) after 6 months therapy with Nilotinib 800 mg/d. Secondary objectives include: - Disease control rate (complete, partial response and stable disease) - Metabolic response - Tolerance NCI CTCAE Version 3.0 - Biomarkers associated to response and disease control.